CDC Updates Recommendations to Allow for Second Covid-19 Booster for Certain Patient Groups
The FDA has amended the emergency use authorizations (EUAs) of Pfizer/BioNTech’s and Moderna’s COVID-19 vaccines to include a second booster dose for adults 50 years of age and older and certain immunocompromised individuals. The second booster doses should be administered at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine.
For certain immunocompromised individuals, the second booster dose of Pfizer/BioNTech’s vaccine is authorized for those 12 years of age and older, and the second booster dose of Moderna’s vaccine is authorized for those 18 years of age and older.
![](https://www.maxor.com/wp-content/uploads/2022/03/covid-table-1024x713.png)
Click here for additional recommendations for immunocompromised people
View Previous Updates